Pqq (Pyrroloquinoline Quinone) for Neuroprotection

Research suggests that PQQ holds significant promise as a neuroprotective compound, with a substantial body of preclinical evidence — including cell culture studies, animal models of stroke, Alzheimer's disease, Parkinson's disease, and folate deficiency — consistently pointing to its ability to reduce oxidative stress, support mitochondrial function, dampen neuroinflammation, and protect the blood-brain barrier through several well-characterized biological pathways. Studies indicate that PQQ appears to work through multiple complementary mechanisms simultaneously, including activation of antioxidant defenses via Nrf2 signaling, suppression of pro-inflammatory NF-κB activity, and upregulation of mitochondrial biogenesis through pathways involving PGC-1α and TFAM, which researchers have proposed makes it a particularly versatile candidate for addressing the multifactorial nature of neurodegeneration. On the human side, two randomized controlled trials in middle-aged and older adults reported statistically significant improvements in several cognitive domains — including memory, attention, and cognitive flexibility — following weeks of PQQ supplementation, and a smaller trial in adults with mild cognitive impairment found increases in a key marker of neuronal health and improved brain metabolic indicators, though these trials were limited by small sample sizes and relatively short durations. Overall, while the direction of the evidence is consistently supportive, the current body of research is weighted heavily toward preclinical work, and the field still awaits larger, longer-term, and more diverse clinical trials to firmly establish optimal use cases, dosing parameters, and long-term safety in human populations.